60 DEGREES PHARMA INC (SXTP) Stock Fundamental Analysis

USA • Nasdaq • NASDAQ:SXTP • US83006G4010

4.16 USD
+0.31 (+8.05%)
At close: Feb 6, 2026
4.0003 USD
-0.16 (-3.84%)
Pre-Market: 2/9/2026, 8:02:00 AM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

2

Overall SXTP gets a fundamental rating of 2 out of 10. We evaluated SXTP against 191 industry peers in the Pharmaceuticals industry. SXTP has a bad profitability rating. Also its financial health evaluation is rather negative. While showing a medium growth rate, SXTP is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • In the past year SXTP has reported negative net income.
  • In the past year SXTP has reported a negative cash flow from operations.
  • In the past 5 years SXTP always reported negative net income.
  • SXTP had a negative operating cash flow in each of the past 5 years.
SXTP Yearly Net Income VS EBIT VS OCF VS FCFSXTP Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 2024 -2M -4M -6M -8M

1.2 Ratios

  • SXTP's Return On Assets of -126.70% is on the low side compared to the rest of the industry. SXTP is outperformed by 82.20% of its industry peers.
  • SXTP's Return On Equity of -191.31% is on the low side compared to the rest of the industry. SXTP is outperformed by 73.30% of its industry peers.
Industry RankSector Rank
ROA -126.7%
ROE -191.31%
ROIC N/A
ROA(3y)-224.71%
ROA(5y)-219.13%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
SXTP Yearly ROA, ROE, ROICSXTP Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 0 -100 -200 -300 -400

1.3 Margins

  • SXTP has a better Gross Margin (42.47%) than 62.30% of its industry peers.
  • SXTP's Gross Margin has declined in the last couple of years.
  • The Profit Margin and Operating Margin are not available for SXTP so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 42.47%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-20.49%
GM growth 5YN/A
SXTP Yearly Profit, Operating, Gross MarginsSXTP Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 2024 0 -500 -1K -1.5K -2K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. Health

2.1 Basic Checks

  • SXTP does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for SXTP has been increased compared to 1 year ago.
  • Compared to 1 year ago, SXTP has a worse debt to assets ratio.
SXTP Yearly Shares OutstandingSXTP Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 100K 200K 300K 400K 500K
SXTP Yearly Total Debt VS Total AssetsSXTP Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 5M 10M 15M 20M

2.2 Solvency

  • SXTP has an Altman-Z score of -8.01. This is a bad value and indicates that SXTP is not financially healthy and even has some risk of bankruptcy.
  • SXTP has a worse Altman-Z score (-8.01) than 68.06% of its industry peers.
  • SXTP has a Debt/Equity ratio of 0.03. This is a healthy value indicating a solid balance between debt and equity.
  • SXTP has a Debt to Equity ratio of 0.03. This is comparable to the rest of the industry: SXTP outperforms 53.40% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.03
Debt/FCF N/A
Altman-Z -8.01
ROIC/WACCN/A
WACC9.43%
SXTP Yearly LT Debt VS Equity VS FCFSXTP Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 0 10M -10M -20M

2.3 Liquidity

  • SXTP has a Current Ratio of 2.87. This indicates that SXTP is financially healthy and has no problem in meeting its short term obligations.
  • SXTP has a Current ratio (2.87) which is in line with its industry peers.
  • A Quick Ratio of 2.63 indicates that SXTP has no problem at all paying its short term obligations.
  • SXTP has a Quick ratio (2.63) which is in line with its industry peers.
Industry RankSector Rank
Current Ratio 2.87
Quick Ratio 2.63
SXTP Yearly Current Assets VS Current LiabilitesSXTP Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 5M 10M 15M 20M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. Growth

3.1 Past

  • SXTP shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 48.68%, which is quite impressive.
  • Looking at the last year, SXTP shows a very strong growth in Revenue. The Revenue has grown by 192.74%.
  • Measured over the past years, SXTP shows a very negative growth in Revenue. The Revenue has been decreasing by -52.49% on average per year.
EPS 1Y (TTM)48.68%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%43.23%
Revenue 1Y (TTM)192.74%
Revenue growth 3Y-52.49%
Revenue growth 5YN/A
Sales Q2Q%291.53%

3.2 Future

  • SXTP is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 25.73% yearly.
  • SXTP is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 48.16% yearly.
EPS Next Y65.93%
EPS Next 2Y34.75%
EPS Next 3Y25.73%
EPS Next 5YN/A
Revenue Next Year164.27%
Revenue Next 2Y81.47%
Revenue Next 3Y82.46%
Revenue Next 5Y48.16%

3.3 Evolution

  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
SXTP Yearly Revenue VS EstimatesSXTP Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2M 4M 6M
SXTP Yearly EPS VS EstimatesSXTP Yearly EPS VS EstimatesYearly EPS VS Estimates 2023 2024 2025 2026 2027 -50 -100 -150 -200

More info and screens

Find the best growth stocksShow best growing peers

1

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for SXTP. In the last year negative earnings were reported.
  • Also next year SXTP is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SXTP Price Earnings VS Forward Price EarningsSXTP Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SXTP Per share dataSXTP EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -5 -10 -15 -20

4.3 Compensation for Growth

  • SXTP's earnings are expected to grow with 25.73% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y34.75%
EPS Next 3Y25.73%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • SXTP does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

60 DEGREES PHARMA INC

NASDAQ:SXTP (2/6/2026, 8:07:38 PM)

Premarket: 4.0003 -0.16 (-3.84%)

4.16

+0.31 (+8.05%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-13
Earnings (Next)N/A
Inst Owners4.94%
Inst Owner Change0%
Ins Owners1.7%
Ins Owner Change2.1%
Market Cap17.60M
Revenue(TTM)1.35M
Net Income(TTM)-8.48M
Analysts82.5
Price Target17.95 (331.49%)
Short Float %N/A
Short Ratio0.06
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)9.43%
Min EPS beat(2)-27.66%
Max EPS beat(2)46.52%
EPS beat(4)1
Avg EPS beat(4)-61.15%
Min EPS beat(4)-247.17%
Max EPS beat(4)46.52%
EPS beat(8)2
Avg EPS beat(8)-34.36%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)14.91%
Min Revenue beat(2)0.28%
Max Revenue beat(2)29.55%
Revenue beat(4)2
Avg Revenue beat(4)-0.75%
Min Revenue beat(4)-29.6%
Max Revenue beat(4)29.55%
Revenue beat(8)2
Avg Revenue beat(8)-18.2%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)300%
PT rev (3m)151.43%
EPS NQ rev (1m)-300%
EPS NQ rev (3m)-103.57%
EPS NY rev (1m)-287.84%
EPS NY rev (3m)-493.49%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)33.75%
Revenue NY rev (1m)0%
Revenue NY rev (3m)35.76%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 12.99
P/FCF N/A
P/OCF N/A
P/B 3.97
P/tB 4.11
EV/EBITDA N/A
EPS(TTM)-23.4
EYN/A
EPS(NY)-7.04
Fwd EYN/A
FCF(TTM)-1.63
FCFYN/A
OCF(TTM)-1.61
OCFYN/A
SpS0.32
BVpS1.05
TBVpS1.01
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -126.7%
ROE -191.31%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 42.47%
FCFM N/A
ROA(3y)-224.71%
ROA(5y)-219.13%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-20.49%
GM growth 5YN/A
F-Score3
Asset Turnover0.2
Health
Industry RankSector Rank
Debt/Equity 0.03
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 112.77%
Cap/Sales 6.26%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.87
Quick Ratio 2.63
Altman-Z -8.01
F-Score3
WACC9.43%
ROIC/WACCN/A
Cap/Depr(3y)258.14%
Cap/Depr(5y)228.76%
Cap/Sales(3y)28.01%
Cap/Sales(5y)17.57%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)48.68%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%43.23%
EPS Next Y65.93%
EPS Next 2Y34.75%
EPS Next 3Y25.73%
EPS Next 5YN/A
Revenue 1Y (TTM)192.74%
Revenue growth 3Y-52.49%
Revenue growth 5YN/A
Sales Q2Q%291.53%
Revenue Next Year164.27%
Revenue Next 2Y81.47%
Revenue Next 3Y82.46%
Revenue Next 5Y48.16%
EBIT growth 1Y16.96%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year12.35%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-47.84%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-49.49%
OCF growth 3YN/A
OCF growth 5YN/A

60 DEGREES PHARMA INC / SXTP FAQ

What is the fundamental rating for SXTP stock?

ChartMill assigns a fundamental rating of 2 / 10 to SXTP.


What is the valuation status of 60 DEGREES PHARMA INC (SXTP) stock?

ChartMill assigns a valuation rating of 1 / 10 to 60 DEGREES PHARMA INC (SXTP). This can be considered as Overvalued.


What is the profitability of SXTP stock?

60 DEGREES PHARMA INC (SXTP) has a profitability rating of 1 / 10.


What is the earnings growth outlook for 60 DEGREES PHARMA INC?

The Earnings per Share (EPS) of 60 DEGREES PHARMA INC (SXTP) is expected to grow by 65.93% in the next year.